Are clinical trials safe?

Yes. Every study on QualifiedStudies is reviewed and approved by an Institutional Review Board (IRB) and conducted under FDA regulations. Research sites are HIPAA-covered entities, and you can withdraw at any time for any reason.

Do I get paid to participate in a clinical trial?

Most studies offer compensation for your time and travel. The amount varies by study length and visit schedule, and is disclosed up front before you enroll.

Is my health information kept private?

Yes. Your information is encrypted, never sold, and only shared with the specific research site you choose to apply to. Our handling of your data is governed by our Consumer Health Data Privacy Policy; the research sites you're matched with are HIPAA-covered entities.

How do I qualify for a clinical trial?

Take our free 60-second eligibility quiz. Enter your ZIP code, condition, and a few health details, and we'll match you with research sites near you that are actively enrolling participants.

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

NCT ID: NCT07105111
Registry status: Recruiting
Study type: Not specified in the registry data
Phase: Phase 4
Sponsor: Neurocrine Biosciences

Overview

ClinicalTrials.gov lists this study as Recruiting.

Enrollment: 100 participants (Estimated).

What is being studied

No interventions are listed in the registry data.

Who may be eligible

Ages: Not specified in the registry data
Sex: Not specified in the registry data
Healthy volunteers accepted: No

ClinicalTrials.gov lists the following eligibility criteria.

Key Inclusion Criteria: * 18 years of age or older * Diagnosed with one of the following at least 3 months prior to screening: schizophrenia or schizoaffective disorder, bipolar disorder, or major depressive disorder * Diagnosed with at least mild neuroleptic-induced TD for at least 3 months prior to screening Key Exclusion Criteria: * Have comorbid Parkinsonism or abnormal involuntary movement(s) that is more prominent than TD * Diagnosis of moderate or severe substance use disorder in the last 6 months * History of long QT syndrome, cardiac arrythmia, or severe hepatic impairment

Study locations

19 study locations are listed.

Site recruitment status is not specified in the registry data for these locations.

Countries: United States

Arkansas, United States: 1
California, United States: 6
Florida, United States: 6
Georgia, United States: 1
Illinois, United States: 1
Nebraska, United States: 1
Ohio, United States: 1
Texas, United States: 1
Virginia, United States: 1

Sample of listed locations

Neurocrine Clinical Site — Bryant, Arkansas, 72022, United States — Site recruitment status not specified in the registry data
Neurocrine Clinical Site — Chino, California, 91710, United States — Site recruitment status not specified in the registry data
Neurocrine Clinical Site — Fresno, California, 93701, United States — Site recruitment status not specified in the registry data
Neurocrine Clinical Site — Long Beach, California, 90807, United States — Site recruitment status not specified in the registry data
Neurocrine Clinical Site — Orange, California, 92866, United States — Site recruitment status not specified in the registry data
Neurocrine Clinical Site — Redlands, California, 92373, United States — Site recruitment status not specified in the registry data
Neurocrine Clinical Site — San Diego, California, 92123, United States — Site recruitment status not specified in the registry data
Neurocrine Clinical Site — Bonita Springs, Florida, 34134, United States — Site recruitment status not specified in the registry data
Neurocrine Clinical Site — Hialeah, Florida, 33012, United States — Site recruitment status not specified in the registry data
Neurocrine Clinical Site — Miami, Florida, 33176, United States — Site recruitment status not specified in the registry data
Neurocrine Clinical Site — Orange City, Florida, 32763, United States — Site recruitment status not specified in the registry data
Neurocrine Clinical Site — Port Charlotte, Florida, 33980, United States — Site recruitment status not specified in the registry data
Neurocrine Clinical Site — Tampa, Florida, 33629, United States — Site recruitment status not specified in the registry data
Neurocrine Clinical Site — Augusta, Georgia, 30912, United States — Site recruitment status not specified in the registry data
Neurocrine Clinical Site — Naperville, Illinois, 60563, United States — Site recruitment status not specified in the registry data
Neurocrine Clinical Site — Omaha, Nebraska, 68124, United States — Site recruitment status not specified in the registry data
Neurocrine Clinical Site — Independence, Ohio, 44131, United States — Site recruitment status not specified in the registry data
Neurocrine Clinical Site — Austin, Texas, 78754, United States — Site recruitment status not specified in the registry data
Neurocrine Clinical Site — Richmond, Virginia, 23226, United States — Site recruitment status not specified in the registry data

Study details

Start date: August 29, 2025
Primary completion date: June 1, 2028
First posted: August 5, 2025

Source and update information

Source: ClinicalTrials.gov
NCT ID: NCT07105111
Registry last updated: September 18, 2026
QualifiedStudies registry data refreshed: September 21, 2026

View NCT07105111 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Depression studies | Clinical trial FAQ